MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control Recruiting nowThis study compares two injectable drugs, bimekizumab and ustekinumab, in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin. Participants will receive either drug for several weeks, and doctor…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New psoriasis pill shows promise in 12-Week trial
Disease control Recruiting nowThis study tests an experimental drug (a TYK2 inhibitor) in 140 adults with moderate to severe plaque psoriasis. Participants will take the drug or a placebo daily for 12 weeks. The main goal is to see if the drug can reduce psoriasis skin symptoms by at least 75% compared to pla…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: NA • Sponsor: Usynova Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab (Bimzelx) passes into the breast milk of mothers who are already taking it for conditions like psoriasis or arthritis. About 20 breastfeeding women will provide milk samples over several weeks. The goal is to understand possibl…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Jun 01, 2026 18:02 UTC